The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
BUSINESS
Kaken Gets Select-Asia Rights to Numab’s Multi-Specific Antibody
Kaken Pharmaceutical said on November 13 that it has signed a strategic licensing and co-development agreement with Swiss biotech Numab Therapeutics for NM81, a novel multi-specific antibody previously known as ND081. The Japanese drug maker exercised its option to acquire…
To read the full story
Related Article
- Kaken Snags Option Rights to Numab’s IBD Drug in Asia
November 18, 2024
- Kaken to Transfer Bispecific IP to J&J as US Giant Nabs Asset
May 30, 2024
- Kaken to Codevelop Novel Multi-Specific Antibody with Swiss Biotech
January 15, 2021
- Kaken, Numab Strike Deal for Multi-Specific Antibody in Inflammatory Disease
June 14, 2017
BUSINESS
- Meiji Restarts Domestic 6-APA Production after 31-Year Hiatus
January 5, 2026
- Meiji Files NDA for Nacubactam in Japan
January 5, 2026
- Sanofi Files Dupixent for CSU in Children Aged 2-11 in Japan
December 26, 2025
- Enhertu Wins 5th China Indication in HER2-Low/Ultralow Breast Cancer
December 26, 2025
- SymBio Bags Rights to Develop Antiviral Brincidofovir for Alzheimer’s
December 26, 2025
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Novartis’ Pluvicto (lutetium vipivotide tetraxetan (177Lu)) won reimbursement listing in Japan in November as a radioligand therapy (RLT) for PSMA-positive…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…